Short answer: It depends on the strength printed on the vial. 2.5 mg of tirzepatide is 50 units at 5 mg/mL, 31.25 units at 8 mg/mL, 25 units at 10 mg/mL, 16.67 units at 15 mg/mL, 12.5 units at 20 mg/mL on a U-100 insulin syringe. The formula is mg ÷ mg/mL × 100 = units. Units measure volume, so they change whenever the vial strength changes.
Rows are the dose steps named in the Mounjaro and Zepbound labels; columns are compounded vial strengths. Each cell is units on a U-100 insulin syringe. Not personalized advice; confirm your dose, in mg and in units, with your prescriber or the dispensing pharmacy.
| Dose | 5 mg/mL | 8 mg/mL | 10 mg/mL | 15 mg/mL | 20 mg/mL |
|---|---|---|---|---|---|
| 2.5 mg | 50 | 31.25 | 25 | 16.67 | 12.5 |
| 5 mg | 100 | 62.5 | 50 | 33.33 | 25 |
| 7.5 mg | 150 (over 1 mL) | 93.75 | 75 | 50 | 37.5 |
| 10 mg | 200 (over 1 mL) | 125 (over 1 mL) | 100 | 66.67 | 50 |
| 12.5 mg | 250 (over 1 mL) | 156.25 (over 1 mL) | 125 (over 1 mL) | 83.33 | 62.5 |
| 15 mg | 300 (over 1 mL) | 187.5 (over 1 mL) | 150 (over 1 mL) | 100 | 75 |
Cells over 100 units need more than one 1 mL syringe. Non-whole numbers fall between printed marks; see how to read insulin syringe marks.
Compounded tirzepatide is dispensed already in solution, at a strength set by the pharmacy. There is no standard; FDA's 2024 alert notes one compounder may offer several concentrations. Pick the page that matches the mg/mL on your label:
| When | Label dose |
|---|---|
| Weeks 1 to 4 | 2.5 mg once weekly (for starting treatment only) |
| Week 5 | 5 mg once weekly |
| Further steps | Increase by 2.5 mg after at least 4 weeks on the current dose |
| Maintenance | 5 mg, 10 mg or 15 mg once weekly for weight reduction; 10 mg or 15 mg for obstructive sleep apnea |
| Maximum | 15 mg once weekly |
The label states that 2.5 mg is for starting treatment and is not an approved maintenance dose.
| When | Label dose |
|---|---|
| Start | 2.5 mg once weekly |
| Further steps | If more glycemic control is needed, increase by 2.5 mg after at least 4 weeks on the current dose |
| Maximum | 15 mg once weekly in adults |
For pediatric patients 10 years and older the Mounjaro label sets a lower maximum of 10 mg once weekly.
FDA has received reports of overdoses, some needing hospital care, from compounded semaglutide in multi-dose vials. In the reports, patients drew more than the prescribed amount, and some prescribers miscalculated the conversion from mg to units; FDA links the errors to confusion between milligrams, milliliters and units. One example FDA gives: a 0.25 mg dose meant to be 5 units was prescribed as 25 units. The insulin syringe guide covers the syringe side of the problem.
Related: Semaglutide units by strength · Tirzepatide guide and powder vials · Ozempic vs Mounjaro